Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

Blood

Volumn 111, Issue 4, 2008, Pages 1834-1839

  Le Coutre, Philipp ^a   Ottmann, Oliver G ^b   Giles, Francis ^c   Kim, Dong Wook ^d   Cortes, Jorge ^c   Gattermann, Norbert ^e   Apperley, Jane F ^f   Larson, Richard A ^g   Abruzzese, Elisabetta ^h   O'Brien, Stephen G ⁱ   Kuliczkowski, Kazimierz ^j   Hochhaus, Andreas ^k   Mahon, Francois Xavier ^l   Saglio, Giuseppe ^m   Gobbi, Marco ⁿ   Kwong, Yok Lam ^o   Baccarani, Michele ^p   Hughes, Timothy ^q   Martinelli, Giovanni ^p   Radich, Jerald P ^r   Zheng, Ming ^s   Shou, Yaping ^s   Kantarjian, Hagop ^c   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d The Catholic University of Korea   (South Korea)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF ROME TOR VERGATA   (Italy)

ⁱ ROYAL VICTORIA INFIRMARY   (United Kingdom)

^j Klinika Hematologii   (Poland)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l HÔPITAL PELLEGRIN   (France)

^m SAN LUIGI GONZAGA HOSPITAL   (Italy)

ⁿ UNIVERSITY OF GENOA   (Italy)

^o QUEEN MARY HOSPITAL   (Hong Kong)

^p UNIVERSITY OF BOLOGNA   (Italy)

^q ROYAL ADELAIDE HOSPITAL   (Australia)

^r USA   (United States)

^s NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; BCR ABL PROTEIN; BILIRUBIN; CYTARABINE; HYDROXYUREA; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; TRIACYLGLYCEROL LIPASE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; CYTOGENETICS; CYTOPENIA; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NAUSEA; NEUTROPENIA; PAIN; PANCREATITIS; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UPPER ABDOMINAL PAIN;

EID: 41349083969     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-04-083196     Document Type: Article

References (19)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian H. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164-172.
2. Sawyers CL, Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340.
3. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol. 1988;25:49-61.
4. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
5. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417.
6. Talpaz M, Silver RT, Druker B, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
7. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441-6.
8. Silver RT, Talpaz M, Sawyers CL, et al. Four years follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large Phase II trials [abstract]. Blood. 2004;104: Abstract 23.
9. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMAWorking Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12:247374-247379.
10. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006;20:1767-1773.
11. Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005;11:4941-4947.
12. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of BCR-ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500-4505.
13. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL. Cancer Cell. 2005;7:129-141.
14. Weisberg E, Manley P, Mestan J, et al. AMN107 (nilotinib): a novel and selective inhibitor of BCRABL. Br J Cancer. 2006;94:1765-1769.
15. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542-2551.
16. Kantarjian HM, Deisseroth A, Kurzrock R, et al. Chronic myelogenous leukemia: a concise update. Blood. 1993;82:691-703.
17. Cortes JE, O'Brien SM, Giles F, et al. Investigational strategies in chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18:619-639.
18. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-2541.
19. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;109:4143-4150.